- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 686549, 12 pages
Virus-Like Particles Containing the Tetrameric Ectodomain of Influenza Matrix Protein 2 and Flagellin Induce Heterosubtypic Protection in Mice
Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA
Received 15 April 2013; Accepted 28 June 2013
Academic Editor: Phillip E. Klebba
Copyright © 2013 Li Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. de Wit and R. A. M. Fouchier, “Emerging influenza,” Journal of Clinical Virology, vol. 41, no. 1, pp. 1–6, 2008.
- G. J. D. Smith, D. Vijaykrishna, J. Bahl et al., “Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza a epidemic,” Nature, vol. 459, no. 7250, pp. 1122–1125, 2009.
- J. P. Tite, C. Hughes-Jenkins, D. O'Callaghan et al., “Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection,” Immunology, vol. 71, no. 2, pp. 202–207, 1990.
- S. L. Epstein, W.-P. Kong, J. A. Misplon et al., “Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein,” Vaccine, vol. 23, no. 46-47, pp. 5404–5410, 2005.
- M. Schotsaert, M. De Filette, W. Fiers, and X. Saelens, “Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments,” Expert Review of Vaccines, vol. 8, no. 4, pp. 499–508, 2009.
- M. De Filette, W. Fiers, W. Martens et al., “Improved design and intranasal delivery of an M2e-based human influenza A vaccine,” Vaccine, vol. 24, no. 44-46, pp. 6597–6601, 2006.
- A. I. Wolf, K. Mozdzanowska, K. L. Williams et al., “Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice,” PLoS ONE, vol. 6, no. 12, Article ID e28445, 2011.
- J. Feng, M. Zhang, K. Mozdzanowska et al., “Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2,” Virology Journal, vol. 3, article 102, 2006.
- F. Steinhagen, T. Kinjo, C. Bode, and D. M. Klinman, “TLR-based immune adjuvants,” Vaccine, vol. 29, no. 17, pp. 3341–3355, 2011.
- B. Z. Wang, H. S. Gill, S. M. Kang, et al., “Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand,” Clinical and Vaccine Immunology, vol. 19, pp. 1119–1125, 2012.
- B.-Z. Wang, R. Xu, F.-S. Quan, S.-M. Kang, L. Wang, and R. W. Compans, “Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection,” PLoS ONE, vol. 5, no. 11, Article ID e13972, 2010.
- B.-Z. Wang, F.-S. Quan, S.-M. Kang, J. Bozja, I. Skountzou, and R. W. Compans, “Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses,” Journal of Virology, vol. 82, no. 23, pp. 11813–11823, 2008.
- K. Yoshioka, S.-I. Aizawa, and S. Yamaguchi, “Flagellar filament structure and cell motility of Salmonella typhimurium mutants lacking part of the outer domain of flagellin,” Journal of Bacteriology, vol. 177, no. 4, pp. 1090–1093, 1995.
- E. Andersen-Nissen, K. D. Smith, K. L. Strobe et al., “Evasion of Toll-like receptor 5 by flagellated bacteria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9247–9252, 2005.
- M. F. Smith Jr., A. Mitchell, G. Li et al., “Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-κB activation and chemokine expression by epithelial cells,” Journal of Biological Chemistry, vol. 278, no. 35, pp. 32552–32560, 2003.
- C. Nempont, D. Cayet, M. Rumbo, C. Bompard, V. Villeret, and J.-C. Sirard, “Deletion of Flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity,” Journal of Immunology, vol. 181, no. 3, pp. 2036–2043, 2008.
- M. De Filette, W. Martens, K. Roose et al., “An influenza A vaccine based on tetrameric ectodomain of matrix protein 2,” Journal of Biological Chemistry, vol. 283, no. 17, pp. 11382–11387, 2008.
- E. V. Vassilieva, B.-Z. Wang, A. N. Vzorov et al., “Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant,” MBio, vol. 2, no. 1, 2011.
- J.-M. Song, B.-Z. Wang, K.-M. Park et al., “Influenza virus-like particles containing M2 induce broadly cross protective immunity,” PLoS ONE, vol. 6, no. 1, Article ID e14538, 2011.
- R. Ito, Y. A. Ozaki, T. Yoshikawa et al., “Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia,” Vaccine, vol. 21, no. 19-20, pp. 2362–2371, 2003.
- J. H. C. M. Kreijtz, R. Bodewes, G. van Amerongen et al., “Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice,” Vaccine, vol. 25, no. 4, pp. 612–620, 2007.
- S. H. S. Sang Heui Seo and R. G. Webster, “Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets,” Journal of Virology, vol. 75, no. 6, pp. 2516–2525, 2001.
- X. Lu, T. M. Tumpey, T. Morken, S. R. Zaki, N. J. Cox, and J. M. Katz, “A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans,” Journal of Virology, vol. 73, no. 7, pp. 5903–5911, 1999.
- A. N. Honko, N. Sriranganathan, C. J. Lees, and S. B. Mizel, “Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis,” Infection and Immunity, vol. 74, no. 2, pp. 1113–1120, 2006.
- M. Vijay-Kumar, F. A. Carvalho, J. D. Aitken, N. H. Fifadara, and A. T. Gewirtz, “TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin,” European Journal of Immunology, vol. 40, no. 12, pp. 3528–3534, 2010.
- A. F. Cunningham, M. Khan, J. Ball et al., “Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1,” European Journal of Immunology, vol. 34, no. 11, pp. 2986–2995, 2004.
- C. Gianfrani, C. Oseroff, J. Sidney, R. W. Chesnut, and A. Sette, “Human memory CTL response specific for influenza a virus is broad and multispecific,” Human Immunology, vol. 61, no. 5, pp. 438–452, 2000.
- A. Jegerlehner, N. Schmitz, T. Storni, and M. F. Bachmann, “Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity,” Journal of Immunology, vol. 172, no. 9, pp. 5598–5605, 2004.
- J. Mestecky and J. R. McGhee, “Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response,” Advances in Immunology, vol. 40, pp. 153–245, 1987.
- G.-G. Zhang, D.-X. Li, H.-H. Zhang, Y.-M. Zeng, and L. Chen, “Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route,” Veterinary Research Communications, vol. 33, no. 7, pp. 735–747, 2009.
- K. Mozdzanowska, D. Zharikova, M. Cudic, L. Otvos, and W. Gerhard, “Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse,” Virology Journal, vol. 4, article 118, 2007.
- M. De Filette, A. Ramne, A. Birkett et al., “The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection,” Vaccine, vol. 24, no. 5, pp. 544–551, 2006.
- Y. Asahi, T. Yoshikawa, I. Watanabe et al., “Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines,” Journal of Immunology, vol. 168, no. 6, pp. 2930–2938, 2002.
- K. B. Renegar, C. D. Johnson, R. C. Dewitt et al., “Impairment of mucosal immunity by total parenteral nutrition: requirement for IgA in marine nasotracheal anti-influenza immunity,” Journal of Immunology, vol. 166, no. 2, pp. 819–825, 2001.
- C. Patry, Y. Sibille, A. Lehuen, and R. C. Monteiro, “Identification of Fcα receptor (CD89) isoforms generated by alternative splicing that are differentially expressed between blood monocytes and alveolar macrophages,” Journal of Immunology, vol. 156, no. 11, pp. 4442–4448, 1996.
- I. Abusugra and B. Morein, “Iscom is an efficient mucosal delivery system for Mycoplasma mycoides subsp. mycoides (MmmSC) antigens inducing high mucosal and systemic antibody responses,” FEMS Immunology and Medical Microbiology, vol. 23, no. 1, pp. 5–12, 1999.
- E. L. Parr and M. B. Parr, “Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2,” Journal of Virology, vol. 72, no. 6, pp. 5137–5145, 1998.